(Q39517276)

12 September 2017

Sex steroid hormones in pairs of tumor and serum from breast cancer patients and pathobiological role of androstene-3β, 17β-diol (English)

1 reference

12 September 2017

2

Shigehira Saji

1 reference

12 September 2017

5

Katsumasa Kuroi

1 reference

12 September 2017

Naoko Honma

1

1 reference

12 September 2017

Makiko Hirose

3

1 reference

12 September 2017

Shin-ichiro Horiguchi

4

1 reference

12 September 2017

Shin-ichi Hayashi

6

1 reference

12 September 2017

Toshiaki Utsumi

7

1 reference

12 September 2017

Nobuhiro Harada

8

1 reference

12 September 2017

10 August 2011

1 reference

12 September 2017

1 reference

12 September 2017

102

1 reference

12 September 2017

10

1 reference

12 September 2017

1848-1854

1 reference

Cancer of the breast: the past decade (first of two parts).

12 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Alternative use of multiple exons 1 of aromatase gene in cancerous and normal breast tissues from women over the age of 80 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

High-sensitivity tandem mass spectrometry assay for serum estrone and estradiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

New quantification method for estradiol in the prostatic tissues of benign prostatic hyperplasia using liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Current and future status of adjuvant therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Estrogen receptor beta in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Steroid metabolism in the hormone dependent MCF-7 human breast carcinoma cell line and its two hormone resistant subpopulations MCF-7/LCC1 and MCF-7/LCC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02018.X

10.1111/J.1349-7006.2011.02018.X

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference